Y1- and α1-receptor control of basal hindlimb vascular tone

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 287, Issue 1 56-1, 2004, Pages

  Jackson, Dwayne N ^a   Noble, Earl G ^a   Shoemaker, J Kevin ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

BIBP3226; Neuropeptide Y; Norepinephrine; Vascular conductance

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y1 RECEPTOR; PRAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ARGININE; DRUG DERIVATIVE; G PROTEIN COUPLED RECEPTOR; NEUROPEPTIDE RECEPTOR; NPY1R PROTEIN, RAT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL TONE; CAROTID ARTERY; CONDUCTANCE; DIASTOLE; HEART RATE; HINDLIMB; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SKELETAL MUSCLE; SYSTOLE; ANIMAL; BLOOD FLOW; BLOOD PRESSURE; DRUG ANTAGONISM; FEMORAL ARTERY; MUSCLE TONE; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ARGININE; BLOOD PRESSURE; FEMORAL ARTERY; HEART RATE; HINDLIMB; MALE; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; REGIONAL BLOOD FLOW;

EID: 3042842901     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00723.2003     Document Type: Article

References (43)

1. Bartfai T, Iverfeldt K, Fisone G, and Serfozo P. Regulation of the release of coexisting neurotransmitters. Annu Rev Pharmacol Toxicol 28: 285-310, 1988.
2. Bouder TG, Huffman LJ, and Hedge GA. Effects of vasoactive intestinal peptide on vascular conductance are unaffected by anesthesia. Am J Physiol Regul Integr Comp Physiol 255: R968-R973, 1988.
3. De Camilli P and Jahn R. Pathways to regulated exocytosis in neurons. Annu Rev Physiol 52: 625-45, 1990.
4. De Potter WP, Kurzawa R, Miserez B, and Coen EP. Evidence against differential release of noradrenaline, neuropeptide Y, and dopamine-β- hydroxylase from adrenergic nerves in the isolated perfused sheep spleen. Synapse 19: 67-76, 1995.
5. De Potter WP, Partoens P, Schoups A, Llona I, and Coen EP. Noradrenergic neurons release both noradrenaline and neuropeptide Y from a single pool: the large dense cored vesicles. Synapse 25: 44-55, 1997.
6. De Potter WP, Partoens P, and Strecker S. Noradrenaline storing vesicles in sympathetic neurons and their role in neurotransmitter release: an historical overview of controversial issues. Neurochem Res 22: 911-919, 1997.
7. Dinenno FA, Jones PP, Seals DR, and Tanaka H. Age-associated arterial wall thickening is related to elevations in sympathetic activity in healthy humans. Am J Physiol Heart Circ Physiol 278: H1205-H1210, 2000.
8. Edvinsson L, Ekblad E, Hakanson R, and Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 83: 519-525, 1984.
9. Ekelund U and Erlinge D. In vivo receptor characterization of neuropeptide Y-induced effects in consecutive vascular sections of cat skeletal muscle. Br J Pharmacol 120: 387-392, 1997.
10. Faber JE. In situ analysis of α-adrenoceptors on arteriolar and venular smooth muscle in rat skeletal muscle microcirculation. Circ Res 62: 37-50, 1988.
11. Grundemar L and Hakanson R. Neuropeptide Y effector systems: perspectives for drug development. Trends Pharmacol Sci 15: 153-159, 1994.
12. Han C and Abel PW. Neuropeptide Y potentiates contraction and inhibits relaxation of rabbit coronary arteries. J Cardiovasc Pharmacol 9: 675-681, 1987.
13. Hess HJ. Prazosin: biochemistry and structure-activity studies. Postgrad Med Spec No: 9-17, 1975.
14. Johnson PC. The myogenic response. News Physiol Sci 6: 41-42, 1991.
15. Joshua IG. Neuropeptide Y-induced constriction in small resistance vessels of skeletal muscle. Peptides 12: 37-41, 1991.
16. Kelly RB. Storage and release of neurotransmitters. Cell 72, Suppl: 43-53, 1993.
17. Lundberg JM, Franco-Cereceda A, Lou YP, Modin A, and Pernow J. Differential release of classical transmitters and peptides. Adv Second Messenger Phosphoprotein Res 29: 223-234, 1994.
18. Mancia G, Ferrari A, Gregorini L, Ferrari MC, Bianchini C, Terzoli L, Leonetti G, and Zanchettie A. Effects of prazosin on autonomic control of circulation in essential hypertension. Hypertension 2: 700-707, 1980.
19. Mancia G, Grassi G, Giannattasio C, and Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34: 724-728, 1999.
20. Massingham R and Hayden ML. A comparsion of the effects of prazosin and hydrallazine on blood pressure, heart rate and plasma renin activity in conscious renal hypertensive dogs. Eur J Pharmacol 30: 121-124, 1975.
21. Matsukawa K and Ninomiya I. Anesthetic effects on tonic and reflex renal sympathetic nerve activity in awake cats. Am J Physiol Regul Regal Integr Comp Physiol 256: R371-R378, 1989.
22. Michel MC and Rascher W. Neuropeptide Y: a possible role in hypertension? J Hypertens 13: 385-395, 1995.
23. Morris M, Kapoor V, and Chalmers J. Plasma neuropeptide Y concentration is increased after hemorrhage in conscious rats: relative contributions of sympathetic nerves and the adrenal medulla. J Cardiovasc Pharmacol 9: 541-545, 1987.
24. Myers AK, Farhat MY, Vaz CA, Keiser HR, and Zukowska-Grojec Z. Release of immunoreactive-neuropeptide by rat platelets. Biochem Biophys Res Commun 155: 118-122, 1988.
25. Oates HF, Graham RM, Stoker LM, and Stokes GS. Haemodynamic effects of prazosin. Arch Int Pharmacodyn Ther 224: 239-247, 1976.
26. 1 receptor. Nat Med 4: 722-726, 1998.
27. Pernow J and Lundberg JM. Neuropeptide Y constricts human skeletal muscle arteries via a nifedipine-sensitive mechanism independent of extracellular calcium? Acta Physiol Scand 128: 655-656, 1986.
28. Pernow J, Svenberg T, and Lundberg JM. Actions of calcium antagonists on pre- and postjunctional effects of neuropeptide Y on human peripheral blood vessels in vitro. Eur J Pharmacol 136: 207-218, 1987.
29. Pons J, Kitlinska J, Ji H, Lee EW, and Zukowska Z. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the β-adrenergic system. Can J Physiol Pharmacol 81: 177-185, 2003.
30. Qureshi NU, Dayao EK, Shirali S, Zukowska-Grojec Z, and Hauser GJ. Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock. Regul Pept 75-76: 215-220, 1998.
31. Rowell LB, Detry JM, Blackmon JR, and Wyss C. Importance of the splanchnic vascular bed in human blood pressure regulation. J Appl Physiol 32: 213-220, 1972.
32. Saleh TM, Connell BJ, and Allen GV. Visceral afferent activation-induced changes in sympathetic nerve activity and baroreflex sensitivity. Am J Physiol Regul Integr Comp Physiol 276: R1780-R1791, 1999.
33. 1-adrenergic blood pressure responses in vivo. Am J Physiol Heart Circ Physiol 275: H760-H766, 1998.
34. Shigeri Y and Fujimoto M. Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neurosci Lett 149: 19-22, 1993.
35. Sundler F, Böttcher G, Ekblad E, and Håkanson R. PP, PYY, and NPY: occurance and distribution in the periphery. In: The Biology of Neuropeptide Y and Related Peptides, edited by Colmers WF and Wahlestedt C. Totowa, NJ: Humana, 1993.
36. Tucker BJ, Peterson OW, Ziegler MG, and Blantz RC. Analysis of adrenergic effects of the anesthetics Inactin and a-chloralose. Am J Physiol Renal Fluid Electrolyte Physiol 243: F253-F259, 1982.
37. Wahlestedt C, Edvinsson L, Ekblad E, and Hakanson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther 234: 735-741, 1985.
38. Wocial B, Ignatowska-Switalska H, Pruszczyk P, Jedrusik P, Januszewicz A, Lapinski M, Januszewicz W, and Zukowska-Grojec Z. Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. Blood Press 4: 143-147, 1995.
39. Zhao XH, Sun XY, Edvinsson L, and Hedner T. Does the neuropeptide Y Y, receptor contribute to blood pressure control in the spontaneously hypertensive rat? J Hypertens 15: 19-27, 1997.
40. Zukowska-Grojec Z. Neuropeptide Y: a novel sympathetic stress hormone and more. Ann NY Acad Sci 771: 219-233, 1995.
41. Zukowska-Grojec Z. Neuropeptide Y: an adrenergic cotransmitter, vasoconstrictor, and a nerve-derived vascular growth factor. Adv Pharmacol 42: 125-128, 1998.
42. Zukowska-Grojec Z, Shen GH, Deka-Starosta A, Myers AK, Kvetnansky R, and McCarty R. Neuronal, adrenomedullary and platelet-derived neuropeptide Y responses to stress in rats. In: Stress: Neuroendocrine and Molecular Approaches, edited by Kvetnansky R. New York: Gordon and Breach, 1992.
43. Zukowska-Grojec Z and Vaz AC. Role of neuropeptide Y (NPY) in cardiovascular responses to stress. Synapse 2: 293-298, 1988.